Search
OPC-28326
go.drugbank.com/drugs/DB05461ExperimentalIt is the only clinical compound with this profile. It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome.
Upanovimab
go.drugbank.com/drugs/DB16505InvestigationalUpanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19
Cocarboxylase
go.drugbank.com/drugs/DB01987ApprovedInvestigationalThe coenzyme form of Vitamin B1 present in many animal tissues. It is a required intermediate in the pyruvate dehydrogenase complex and the ketoglutarate dehydrogenase complex.
Mepartricin
go.drugbank.com/drugs/DB13633InvestigationalCategories: Drugs Used in Benign Prostatic HypertrophyRAPA-501-Allo
go.drugbank.com/drugs/DB15890InvestigationalRAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]
Atipamezole
go.drugbank.com/drugs/DB11481InvestigationalVet approvedAtipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs. … It has also been undergone research as a potential anti-Parkinsonian drug for humans.
Categories: Adrenergic alpha-2 Receptor AntagonistsCinalukast
go.drugbank.com/drugs/DB00587ExperimentalUsed in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. … Cinalukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
Perifosine
go.drugbank.com/drugs/DB06641InvestigationalPerifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.
Dacetuzumab
go.drugbank.com/drugs/DB12589InvestigationalIt is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. … Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse.